Episodes

  • Pure Global: Malaysia's MedTech Handshake, ASEAN's New Shortcut

    Pure Global: Malaysia's MedTech Handshake, ASEAN's New Shortcut
    Mar 31 2026
    In this episode of MedTech Global Insights, we unpack the most significant regulatory shift in Southeast Asia this year. The costly and time-consuming process of seeking individual device approvals in each country is being replaced by a powerful new trend: regulatory reliance. We dive into the new pilot program between Malaysia and Thailand that is creating an expedited pathway for market access. Imagine your company just spent two years and a significant budget getting your device approved in one country. Now you face the same mountain in the neighboring market. What if there was a way to use your existing approval to cut the next timeline in half? This is the reality that new ASEAN reliance programs are creating, but navigating them requires insider knowledge. This week's insights: - What exactly is the new Malaysia-Thailand regulatory reliance pilot program? - How does this "shortcut" actually accelerate your market entry process? - Which specific device classes are most likely to benefit? - Is this a one-off deal or part of a larger strategic trend in Southeast Asia? - How can approvals from the US or EU be leveraged in this new framework? - What are the hidden risks or documentation requirements for using these pathways? - How does this fundamentally change the strategy for MedTech expansion into Asia? - Which country's approval now offers the best "gateway" to the broader ASEAN region? For a deeper conversation on building your global strategy, contact us at info@pureglobal.com or visit https://pureglobal.com/. You can also explore our FREE AI tools and medical device database at https://pureglobal.ai/.
    Show more Show less
    2 mins
  • Pure Global: EU's MedTech Shortage & The New Supply Rules

    Pure Global: EU's MedTech Shortage & The New Supply Rules
    Mar 30 2026
    The European Union is taking decisive action to combat the critical shortage of medical devices, a problem that has plagued its healthcare systems since the rollout of MDR. This episode unpacks the European Commission's new proposal for a mandatory six-month notification period for discontinuing devices, and what it means for manufacturers. This isn't just another form to fill out. it's a fundamental shift in market responsibility that directly impacts product lifecycle management, supply chain forecasting, and your competitive position. We explore the strategic challenges and opportunities this new era of mandatory transparency creates for MedTech companies operating in the EU. A French manufacturer of a critical diagnostic assay decides to discontinue the product due to low margins and high MDR compliance costs. Their plan was to quietly phase it out within three months. Suddenly, they are faced with the new six-month mandatory notification rule, forcing them to continue production at a loss, manage difficult conversations with distributors, and alert competitors to their exit strategy far earlier than intended, creating a significant strategic dilemma. Key Takeaways: - What triggers the mandatory six-month shortage notification requirement in the EU? - How does this new rule change the financial calculation for discontinuing a legacy product? - What specific information must manufacturers now provide to competent authorities? - How can you turn supply chain transparency into a competitive advantage in the EU market? - What are the legal and commercial risks of failing to comply with this new proposal? - How should this rule affect your product portfolio and end-of-life strategies? - Does this new EU rule align with or diverge from supply notification rules in the US or other markets? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.
    Show more Show less
    2 mins
  • Pure Global: Germany's AI Device Sudden Compliance Shock.

    Pure Global: Germany's AI Device Sudden Compliance Shock.
    Mar 29 2026
    This week, MedTech Global Insights explores the seismic shift in European regulations for AI-powered medical devices. A major EU Notified Body has dropped a new, mandatory cybersecurity guidance document, sending shockwaves through the industry by demanding retroactive compliance. We unpack what this means for manufacturers, from agile startups to global giants. We explore the stringent new requirements for a Software Bill of Materials (SBOM) and penetration testing, and the immediate compliance scramble that is turning a regulatory update into a high-stakes business challenge. Consider this case: a promising MedTech company's leading AI diagnostic software, already on the market, is suddenly facing delisting. This is the reality for innovators who now must prove end-to-end digital safety based on rules that didn't exist when they got their approval. Their pain is a warning for all that market access is not guaranteed to last. Key Takeaways: - Why is a Software Bill of Materials suddenly a deal-breaker for EU market access? - What are the three biggest cybersecurity vulnerabilities that regulators are targeting now? - Could your existing CE mark be invalidated by a post-market guidance update? - What are the hidden operational costs of this new compliance scramble? - How does this shift the definition of market-readiness for all software-based medical devices? - Is this new regulation a barrier to entry, or an opportunity for prepared firms? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/. You can also visit https://pureglobal.ai/ for FREE AI tools and a free medical device database.
    Show more Show less
    2 mins
  • USA's QMSR Shockwave: Pure Global on Surviving FDA's New Audit Game

    USA's QMSR Shockwave: Pure Global on Surviving FDA's New Audit Game
    Mar 28 2026
    The FDA has officially replaced the long-standing QSIT inspection model with a new approach under the Quality Management System Regulation (QMSR). This shift towards harmonization with ISO 13485 introduces a more holistic, risk-based auditing process, catching many MedTech manufacturers off guard and rendering their old preparation methods obsolete. This episode of MedTech Global Insights dives into what this change really means for your operations. We explore the critical differences between the old and new inspection techniques and the immediate impact on quality assurance teams. **Case In Point:** A manufacturer of infusion pumps, confident in their CAPA and Design Control subsystems, recently faced a QMSR audit. Instead of following the old checklist, the inspector focused entirely on the risk management files and post-market complaint data for a single product line, uncovering gaps in their risk-to-complaint process that the previous QSIT audit never would have flagged. **In This Episode, We Ask:** - Is your quality system truly integrated, or just a collection of compliant subsystems? - How does the new QMSR inspection approach change the way you should manage suppliers? - What are the key differences in documentation an investigator will now demand? - Does your current risk management process stand up to a full product lifecycle trace audit? - How can you leverage your ISO 13485 certification for the new FDA inspections? - What immediate changes should you make to your internal audit program? - Are your teams trained to speak to processes and risks, not just procedures? To ensure your quality system is ready for this new era, contact us at info@pureglobal.com or visit https://pureglobal.com/. For free AI tools and access to a comprehensive medical device database, visit https://pureglobal.ai/.
    Show more Show less
    2 mins
  • USA's FDA QMSR: Pure Global on Hidden Management Liability

    USA's FDA QMSR: Pure Global on Hidden Management Liability
    Mar 27 2026
    This week, MedTech Global Insights dives into the most significant U.S. regulatory shift of 2026: the FDA's new Quality Management System Regulation (QMSR). We uncover why this is far more than a simple alignment with international standards and exposes a new level of corporate liability. The episode reveals how FDA inspectors now have unprecedented access to high-level management review meetings. We explore a real-world case where a company's internal decision to 'monitor' a component risk, once a private discussion, is now a transparent record for regulators, potentially creating massive legal and financial exposure after a single patient incident. Key Takeaways: - Why is the FDA's new QMSR more than just a paperwork update? - What specific internal documents are now exposed to FDA inspectors for the first time? - How does this rule change the personal liability of your executive team? - Is your current "quality culture" strong enough to withstand direct regulatory scrutiny? - What's the number one mistake companies are making in their management review meetings right now? - How can you turn this new regulatory pressure into a competitive advantage? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.
    Show more Show less
    2 mins
  • Pure Global: USA MedTech Security & Why FDA's Honeymoon Is Over

    Pure Global: USA MedTech Security & Why FDA's Honeymoon Is Over
    Mar 26 2026
    The FDA's "honeymoon phase" for medical device cybersecurity is over. In this episode, we dissect the agency's heightened scrutiny on premarket submissions, moving beyond simple documentation to active verification. We explore the new, unwritten rules manufacturers must follow to avoid costly rejections. We look at the case of a company whose 510(k) submission was delayed for months. Despite providing a complete Software Bill of Materials (SBOM), they were rejected because a common open-source library had a vulnerability. Their pain point was the failure to provide a VEX document to prove the vulnerability was not exploitable in their device, a detail that has become a silent requirement for approval. Key Takeaways: - Why is a complete SBOM no longer sufficient for an FDA submission? - How is the FDA using public databases to challenge your device's security in real-time? - What is a VEX document and how can it rescue your submission from an almost certain rejection? - Can you prove your Secure Product Development Framework is truly "built-in" and not just "bolted-on"? - What is the most critical question to answer about your vulnerability management plan? - How do you address the ticking time bomb of legacy device security? - What are the three essential components of a security narrative that the FDA now expects to see? For more information, contact us at info@pureglobal.com or visit https://pureglobal.com/. Explore our FREE AI tools and medical device database at https://pureglobal.ai/.
    Show more Show less
    2 mins
  • USA 510(k) Cybersecurity: The 'Refuse to Accept' Trap | Pure Global

    USA 510(k) Cybersecurity: The 'Refuse to Accept' Trap | Pure Global
    Mar 25 2026
    The FDA has drawn a new line in the sand for medical device market access, and non-compliance means immediate rejection. With the full implementation of Section 524B of the FD&C Act, robust cybersecurity documentation is no longer optional for any 510(k) submission of a connected "cyber device." This episode breaks down the critical new requirements that are already impacting market entry timelines. We explore the costly lesson of a European AI startup whose promising 510(k) submission was instantly rejected with a "Refuse to Accept" letter. Their mistake wasn't in the clinical data, but in their failure to provide a Software Bill of Materials (SBOM) and a post-market vulnerability plan, causing a six-month delay and putting their funding at risk. This is the new reality of entering the US market. This week's insights: - What is the FDA's new line in the sand for medical device cybersecurity? - Is your device a "cyber device" and what does that legally require now? - What is a Software Bill of Materials (SBOM) and why is it non-negotiable? - How can a simple documentation gap lead to a costly "Refuse to Accept" letter? - What post-market monitoring plan does the FDA now expect to see *before* you go to market? - Why is your engineering team's process now a critical part of your regulatory submission? Contact us at info@pureglobal.com or visit https://pureglobal.com/ or visit https://pureglobal.ai/ for FREE AI tools and free medical device database.
    Show more Show less
    2 mins
  • U.S. AI Medical Devices: Cracking the New Code | Pure Global

    U.S. AI Medical Devices: Cracking the New Code | Pure Global
    Mar 24 2026
    This week on MedTech Global Insights, we dissect the groundbreaking new draft guidance from the U.S. FDA on AI and Machine Learning medical devices. This pivotal announcement introduces new requirements for adaptive algorithms, fundamentally changing the regulatory landscape for software as a medical device (SaMD) manufacturers worldwide. We explore what the new "Predetermined Change Control Plan" means for your technical dossier, validation strategies, and post-market surveillance. We break down the ripple effects this will have on other major markets and discuss the strategic adjustments companies must now consider to ensure successful global market access. Imagine a promising European startup with a revolutionary AI diagnostic tool, fully certified for the EU market. They've invested millions and are ready for U.S. expansion. Suddenly, the new FDA guidance renders their existing validation data insufficient. They now face a costly, time-consuming overhaul of their entire regulatory strategy, putting their funding and market lead at risk. Key Takeaways: - What are the three biggest changes in the new FDA AI/ML guidance? - How does a "Predetermined Change Control Plan" work in practice? - Will my existing clinical validation data be accepted under these new U.S. rules? - How does this impact MedTech companies based outside of the United States? - What are the new expectations for post-market surveillance of learning algorithms? - Is the European Union likely to adopt a similar framework for AI devices? - How can startups navigate these new regulatory hurdles without a massive budget? - What's the key difference between the FDA's approach and the EU's AI Act for MedTech? For more insights, contact us at info@pureglobal.com or visit https://pureglobal.com/. You can also access our FREE AI tools and medical device database at https://pureglobal.ai/.
    Show more Show less
    2 mins